Corient Private Wealth
ITOS

Corient Private Wealth’s iTeos Therapeutics ITOS Stock Holding History

Corient Private Wealth’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-12,889
Closed -$141K – 2302
2023
Q3 		$141K Buy
+12,889
New +$165K ﹤0.01% 1984

Other funds holding ITOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Corient Private Wealth's ITOS Position: Q4 2023 in Review

Corient Private Wealth sold out of iTeos Therapeutics (ITOS) in Q4 2023, closing a stake of 12,889 shares — an estimated $141K sold.

Corient Private Wealth first reported a position in ITOS in Q3 2023 and held it in 1 quarter. The position peaked at $141K in Q3 2023. 137 funds tracked by Wall St. Rank hold ITOS as of Q4 2023.

  • Corient Private Wealth reported no remaining iTeos Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Corient Private Wealth sold 12,889 iTeos Therapeutics shares in Q4 2023, an estimated $141K.
  • Corient Private Wealth first reported a position in iTeos Therapeutics in Q3 2023 and held it in 1 quarter.
  • Corient Private Wealth's iTeos Therapeutics position peaked at $141K in Q3 2023.
  • 137 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q4 2023.

Based on Corient Private Wealth's 13F filing for Q4 2023, filed 9 Feb 2024.